A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting
2d agoen
From the article
Conditions : Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer; Folate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube Cancer; Folate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer Sponsors : AbbVie Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Ovarian cancer drug mirvetuximab improves quality of life for patients, UK women report
A new ovarian cancer drug called mirvetuximab is offering women more time and a better quality of life compared to standard chemotherapy. Pa
Real-World EV Plus Pembro Success Seen in Urothelial Cancer
Medscape·19h ago

Una nueva terapia logra atacar el cáncer de ovario reduciendo el daño a las células sanas
Infobae·2d ago
https://doi.org/10.1056/NEJMoa2517384
doi.org·1mo ago
Two Observational Studies Link GLP-1 Receptor Agonists to Reduced Breast Cancer Risk in Women with Obesity
Two observational studies found that GLP-1 receptor agonists (like Ozempic, Wegovy) are associated with reduced breast cancer incidence in w

Comments
Sign in to join the conversation.
No comments yet. Be the first.